Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 Trial.

MLA

Natsuaki, Masahiro, et al. “Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 Trial.” Journal of the American Heart Association, vol. 13, no. 15, Aug. 2024, p. e034201. EBSCOhost, https://doi.org/10.1161/JAHA.123.034201.

APA

Natsuaki, M., Watanabe, H., Morimoto, T., Yamamoto, K., Obayashi, Y., Nishikawa, R., Ando, K., Suwa, S., Isawa, T., Takenaka, H., Ishikawa, T., Yamada, M., Wakatsuki, T., Nozaki, Y., Kitahara, H., Kato, R., Kawai, R., Kobayashi, Y., Ishii, M., … Kimura, T. (2024). Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 Trial. Journal of the American Heart Association, 13(15), e034201. https://doi.org/10.1161/JAHA.123.034201

Chicago

Natsuaki, Masahiro, Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, Yuki Obayashi, Ryusuke Nishikawa, Kenji Ando, et al. 2024. “Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 Trial.” Journal of the American Heart Association 13 (15): e034201. doi:10.1161/JAHA.123.034201.